Methylin: What is the Generic Version of This ADHD Medication?
Methylin, containing methylphenidate hydrochloride, is a prescription medication primarily used to treat attention deficit hyperactivity disorder (ADHD) and certain cases of narcolepsy.
Why is Methylin Still Prescribed When There's a Generic Alternative?
Despite being available under a generic name, Methylin remains widely prescribed due to its controlled-release formulation, Methylin ER, which is not available as an exact generic equivalent.
Generic Methylin Alternatives: What You Need to Know
As of [1], generic methylphenidate hydrochloride is available in various formulations, including immediate-release and extended-release tablets. These generic alternatives often come from multiple manufacturers, such as Teva, Mylan, and Lupin.
Some examples of generic Methylin alternatives include:
* Ritalin (Novartis)
* Methylin ER (Mallinckrodt)
* Equasym XL (Sanofi-Aventis)
* Metadate CD (Mallinckrodt)
How Do These Generic Alternatives Compare to Methylin?
The generic versions of methylphenidate hydrochloride are expected to have similar efficacy, safety, and side effect profiles as the brand-name counterpart. However, the exact generic alternative may not contain all the inactive ingredients present in the original formulation, which could potentially cause issues in sensitive patients.
What Happens When Methylin's Patent Expires?
The patent for Methylin ER, which is the controlled-release formulation of the medication, is expected to expire in [2]. However, it's essential to note that brand manufacturers may still be able to maintain market exclusivity through secondary patents, which could limit the availability of generic alternatives.
When Does Exclusivity Expire for Methylin?
According to DrugPatentWatch.com [3], the patent for Methylin ER, which contains methylphenidate hydrochloride, is set to expire in [Year, date]. After the patent expires, generic manufacturers will receive approval to market their versions of the medication.
Sources:
[1] FDA - Methylphenidate Hydrochloride Extended-Release Tablets (2023)
[2] DrugPatentWatch.com - Patent Expiration Dates for Methylphenidate Hydrochloride Extended-Release Tablets (2023)
[3] DrugPatentWatch.com - Patent Expiration Dates for Methylin ER (2023)